BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the third quarter ended September 30, 2025, and ...

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

Thank you, operator. Good morning and good afternoon, everybody, and thank you for joining BioNTech's Third Quarter 2025 Earnings Call. As a reminder, the slides we'll use during the call and the ...
Le Lézard

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the third quarter ended September 30, 2025 and ...
Finanznachrichten

Karyopharm Therapeutics Inc.: Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

In addition, preliminary blinded aggregate safety data from the first 61 patients with a median follow-up of greater than 12 months may suggest improvements in both hematologic and non-hematologic ...

Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.
Le Lézard

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended September 30, 2025, ...

Nuvation Bio signals $55M annualized IBTROZI revenue potential as DOR reaches 50 months, supported by rapid market expansion

Discover key insights from Nuvation Bio's Q3 2025 earnings: rapid IBTROZI uptake, strong financials, and growth strategies in oncology.

Versatile gene-switch tool uses non-toxic molecule for safer research

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

Chronic Progressive Multiple Sclerosis Market to Witness Accelerated Expansion During the Forecast Period (2025-2034) Due to Strong Pipeline and Advanced Thera…

The chronic progressive multiple sclerosis market size is anticipated to grow during the forecast period (2025–2034).
The Manila Times

BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor ...

Novel approach designed to address dysregulated RNA splicing events that drive tumor growth and disease progression across multiple hematological malignancies ...

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow UpLifileucel Launch in Previously Treated Advanced ...
The Manila Times

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on ...